HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Hold Public Meeting In February on Cosmetic Talc-Asbestos Test Methods

Executive Summary

Recommendations from an FDA-led interagency work group regarding methods for detecting and measuring asbestos in talc and talc-containing cosmetics will be presented at the agency’s planned public meeting in Silver Spring, MD, on 4 February. The recommendations are summarized in the FDA's meeting notice, which follows contentious cosmetic product recalls based on asbestos findings.

You may also be interested in...



FDA-Proposed Talc Testing Methods Likely Would Find Particles Of Concern; Then What?

The FDA is focused on driving adoption of more sensitive, standardized testing methods for assessing cosmetic talc purity, which it believes would yield more consistent results across labs. This would help to inform research into the health implications of trace levels of asbestos and other elongate mineral particles in talc; in the interim it could to be damaging to companies that supply or use that talc.

50 Years Later, FDA And Cosmetics Industry At Odds Again Over Asbestos

The Personal Care Products Council says talc-testing methods in the cosmetics industry must distinguish between carcinogenic asbestos and harmless non-asbestiform minerals, recalling its position against the FDA’s stab at rulemaking in 1973. However, the FDA is now arguing that elongate mineral particles of respirable dimensions are inherently dangerous, regardless of other considerations.

J&J International Baby, Beauty Lines Could Lead Trimming 10% Of Consumer Portfolio

J&J plans to cut 10% of its consumer health portfolio, with most divestitures in the baby and beauty care segments outside the US. It plans to focus on growing “stronghold” categories of skin health and self care, including Aveeno and Tylenol.

Related Content

Topics

UsernamePublicRestriction

Register

RS149592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel